Unusual Options Activity In JD inc (JD)
10691 $JD MAY 16th 2025 34.00 CALLS BOUGHT@ 2.94 vs Open Interest of 163 for a total of $3143154 on the BULL side
10691 $JD MAY 16th 2025 34.00 CALLS BOUGHT@ 2.94 vs Open Interest of 163 for a total of $3143154 on the BULL side
Digital Realty is a real estate investment trust that owns, operates and invests in carrier-neutral data centers across the world. The company offers data center, colocation and interconnection services. As of June 2023, Digital Realty has 300+ facilities in 50+ metros across 25+ countries on six continents
NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG.
NextEra Energy, Inc. is an American energy company with about 58 GW of generating capacity, revenues of over $18 billion in 2020, and about 14,900 employees throughout the US and Canada
eBay Inc. is an American multinational e-commerce company based in San Jose, California,
Avantor is an American biotechnology, chemicals, and pharmaceuticals company headquartered in Radnor, Pennsylvania. The company ranked 484th on the 2020 Fortune 500, based on its 2019 sales.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.